We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+14.39%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.85B
AUM Growth
+$177M
Cap. Flow
-$53.9M
Cap. Flow %
-1.89%
Top 10 Hldgs %
28.19%
Holding
216
New
12
Increased
42
Reduced
44
Closed
16

Top Buys

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$46M
2
DHR icon
Danaher
DHR
+$34.4M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$30.2M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$22.3M
5
DXCM icon
DexCom
DXCM
+$20M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$44.2M
2
MRK icon
Merck
MRK
+$39.7M
3
PFE icon
Pfizer
PFE
+$39.7M
4
ABBV icon
AbbVie
ABBV
+$24.5M
5
CNC icon
Centene
CNC
+$23.8M

Sector Composition

Rank Sector Weight
1 Healthcare 95.34%
2 Real Estate 2.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TEVA icon
101
Teva Pharmaceuticals
TEVA
$40B
$7.04M 0.25%
730,051
-55,800
-7% -$535K
CRL icon
102
Charles River Laboratories
CRL
$11.3B
$7.04M 0.25%
28,154
-2,600
-8% -$619K
TGTX icon
103
TG Therapeutics
TGTX
$7.4B
$6.93M 0.24%
+133,269
New +$4.5M
XNCR icon
104
Xencor
XNCR
$1.48B
$6.47M 0.23%
148,231
– –
ARVN icon
105
Arvinas
ARVN
$573M
$6.24M 0.22%
+73,459
New +$2.53M
A icon
106
Agilent Technologies
A
$39.2B
$6.22M 0.22%
52,525
– –
TFX icon
107
Teleflex
TFX
$6.22B
$6.2M 0.22%
15,052
-2,200
-13% -$812K
DNLI icon
108
Denali Therapeutics
DNLI
$3.83B
$6.06M 0.21%
+72,333
New +$4.37M
RVNC
109
DELISTED
Revance Therapeutics, Inc.
RVNC
$6.06M 0.21%
213,808
+127,968
+149% +$3.31M
COGT icon
110
Cogent Biosciences
COGT
$7.3B
$6.04M 0.21%
537,742
+261,948
+95% +$2.88M
BCEL
111
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$5.69M 0.2%
352,424
– –
AMED
112
DELISTED
Amedisys
AMED
$5.69M 0.2%
19,395
– –
SRRK icon
113
Scholar Rock
SRRK
$5.73B
$5.63M 0.2%
+116,094
New +$4.22M
ALGN icon
114
Align Technology
ALGN
$12.4B
$5.37M 0.19%
10,041
– –
RVTY icon
115
Revvity
RVTY
$12.3B
$5.32M 0.19%
37,094
-1,400
-4% -$186K
VRNA
116
DELISTED
Verona Pharma
VRNA
$5.26M 0.18%
751,905
+276,503
+58% +$1.87M
FMTX
117
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$5.23M 0.18%
+149,825
New +$6.52M
ZLAB icon
118
Zai Lab
ZLAB
$2.08B
$5.08M 0.18%
37,523
– –
CNC icon
119
Centene
CNC
$31.7B
$5.05M 0.18%
84,145
-374,168
-82% -$23.8M
RETA
120
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$4.72M 0.17%
38,219
-38,221
-50% -$5.02M
DOC icon
121
Healthpeak Properties
DOC
$14.9B
$4.55M 0.16%
150,392
– –
NVO
122
Novo Nordisk
NVO
$197B
$4.53M 0.16%
129,812
-138,198
-52% -$4.78M
QURE icon
123
uniQure
QURE
$3.04B
$4.52M 0.16%
125,003
+61,964
+98% +$2.61M
ADUS icon
124
Addus HomeCare
ADUS
$2.16B
$4.41M 0.15%
37,640
+21,671
+136% +$2.24M
SNN icon
125
Smith & Nephew
SNN
$12.8B
$4.2M 0.15%
99,560
– –
3 4
5
6 7

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, Tekla Capital Management held 216 positions worth $2.85B, up 6.6% from $2.67B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Tekla Capital Management's Q4 2020 filing shows 12 new, 42 increased, 44 reduced and 16 closed positions. Its largest new stake was Teladoc Health: 56,520 shares worth $11.3M. The largest sale was Amgen, an estimated $44.2M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q4 2020 buy was Teladoc Health: 56,520 shares worth $11.3M.
  • Tekla Capital Management added most to Thermo Fisher Scientific in Q4 2020, an estimated $46M increase.
  • Tekla Capital Management's biggest Q4 2020 reduction was Amgen, cutting an estimated $44.2M.
  • Tekla Capital Management fully exited Immunomedics Inc in Q4 2020, selling an estimated $19M.
  • Tekla Capital Management's ten largest holdings make up 28% of its $2.85B portfolio in Q4 2020.
  • Tekla Capital Management opened 12 new positions and closed 16 in Q4 2020.
  • Tekla Capital Management's portfolio value rose 6.6% quarter-over-quarter to $2.85B.

Based on Tekla Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.